Navigation Links
Thoratec Announces Presentations at Upcoming Investor Conferences
Date:3/3/2011

PLEASANTON, Calif., March 3, 2011 /PRNewswire/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in two upcoming investor conferences.

On Monday, March 7, the company will participate in the Raymond James 32nd Annual Institutional Investors Conference. David V. Smith, executive vice president and chief financial officer, will provide an update on the company, beginning at 11 a.m., Eastern Standard Time (8 a.m., Pacific Standard Time). The presentation will be available through the conference web site at http://www.wsw.com/webcast/rj62/thor/, or on the company's web site at http://www.thoratec.com.

On Wednesday, March 16, Thoratec will present at the Barclays Capital 2011 Global Healthcare Conference. The presentation by David V. Smith will begin at 9 a.m., Eastern Daylight Time (6 a.m., Pacific Daylight Time) and can be accessed through the conference web site at http://cc.talkpoint.com/barc002/031511a_rb/?entity=92_QCE2BWS, or on the company's website at http://www.thoratec.com.

Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 15,000 devices implanted in patients suffering from heart failure. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web site at http://www.thoratec.com.

Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec Corporation.


'/>"/>
SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
5. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
6. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
7. Thoratec Presentation at Canaccord Adams Conference to be Webcast
8. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
9. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
10. Thoratec Presentation at Piper Jaffray Conference to be Webcast
11. Thoratec Presentation at Raymond James Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2017)... WAYNE, N.J. , May 3, 2017 /PRNewswire/ ... systems that contribute to quality enhancement and cost ... results from a study of contemporary practice demonstrating ... a first-line therapy for critically ill patients. The ... the Company,s newer large volume MEGA ® ...
(Date:5/2/2017)... YORK and LONDON , ... of market intelligence, MarketResearch.com is pleased to announce a ... AB that allows for the marketing and distribution ... analyses through the MarketResearch.com website. The new ... to complete product descriptions and tables of contents from ...
(Date:5/2/2017)... , May 2, 2017  CIVCO Radiotherapy, the ... solutions, announced today that Nat Geissel ... CIVCO since 2012 and has served as vice ... vice president and general manager, and most recently, ... "I am extremely proud of what CIVCO Radiotherapy ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... 2017 , ... If you are thinking of a visit to San Francisco , fall ... the perfect time to visit. , Business Architecture Associates is pleased to offer 5 days ... as a 4-½ day package for individuals, and as 4-½ day corporate package for up ...
(Date:5/24/2017)... Chicago, IL (PRWEB) , ... May 24, 2017 ... ... of the most prominent for-profit and nonprofit hospitals and health systems in the ... have turned around their institutions, led professional organizations and been instrumental in developing ...
(Date:5/24/2017)... Shoreview, MN (PRWEB) , ... May 24, 2017 ... ... manufacturer of polyvinylidene fluoride (PVDF) based sleep diagnostics sensors, announced today it had ... network now consists of a mix of domestic and rest of world (ROW) ...
(Date:5/23/2017)... ... ... Allegheny Health Network and the Alexis Joy D’Achille Foundation ... at West Penn Hospital , a unique facility that will offer the most ... Construction of the Center is underway with a scheduled opening in the fall of ...
(Date:5/23/2017)... ... , ... New England Journal Of Medicine Confirms Viability of Rory’s Regulations and ... Staunton Foundation Calls on Health & Human Services, Tom Price to Adopt Rory’s Regulations ... today reported on a new study released on May 21, 2017 in the New ...
Breaking Medicine News(10 mins):